Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung

Does the Measure of the Plasma Tissue Factor Allow to Predict a Venous Thromboembolism Episode for Patients Presenting a Primitive Lung Cancer?

The aim of the study is to evaluate if the plasma activity of the tissue factor at the time of the diagnosis of a lung cancer, before any treatment, or after the treatment of induction (surgery or two first cures of chemotherapy), can be a predictive factor of venous thromboembolism disease in the year which follows the diagnosis, independently of the other parameters.

Inclusion Criteria:

• Patients of more than 18 years old
• Patients with cancer of lung diagnosis carried for less than 2 months and which were not handled yet, either by surgery or by chemotherapy, or by radiotherapy
• Patients whose life expectancy is considered 3-month-old a superior
• Patients having given writed consent
• Patients affiliated to a national insurance scheme or benefiting from such a diet
• Patients having received a treatment (processing) anticoagulating in preventive dose if this treatment was stopped at least 3 days before the 1st taking or patients not receiving an anticoagulating treatment (in case of curative treatment, the latter was before arrested at least 3 months

Exclusion Criteria:

• Patients having a hepatic disease with coagulation disorders
• Patients under anticoagulants with dose guardian in 3 months preceding the study or presenting an active infection
• Patients having a history of other cancer considered as cured and diagnosed for less than 5 years (with the exception of the patients operated for an in situ carcinoma of the neck of the womb or the patients having undergone the excision of a squamous-cell carcinoma)